It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective
Prostate cancer is the second most common cancer in men worldwide and is associated with high morbidity and mortality. Consequently, there is an urgent unmet need for novel treatment avenues. In addition to somatic genetic alterations, deviations in the epigenetic landscape of cancer cells and their...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/2/294 |
| _version_ | 1797344481898397696 |
|---|---|
| author | Anniek Zaalberg Elisabeth Pottendorfer Wilbert Zwart Andries M. Bergman |
| author_facet | Anniek Zaalberg Elisabeth Pottendorfer Wilbert Zwart Andries M. Bergman |
| author_sort | Anniek Zaalberg |
| collection | DOAJ |
| description | Prostate cancer is the second most common cancer in men worldwide and is associated with high morbidity and mortality. Consequently, there is an urgent unmet need for novel treatment avenues. In addition to somatic genetic alterations, deviations in the epigenetic landscape of cancer cells and their tumor microenvironment (TME) are critical drivers of prostate cancer initiation and progression. Unlike genomic mutations, epigenetic modifications are potentially reversible. Therefore, the inhibition of aberrant epigenetic modifications represents an attractive and exciting novel treatment strategy for castration-resistant prostate cancer patients. Moreover, drugs targeting the epigenome also exhibit synergistic interactions with conventional therapeutics by directly enhancing their anti-tumorigenic properties by “priming” the tumor and tumor microenvironment to increase drug sensitivity. This review summarizes the major epigenetic alterations in prostate cancer and its TME, and their involvement in prostate tumorigenesis, and discusses the impact of epigenome-targeted therapies. |
| first_indexed | 2024-03-08T11:03:15Z |
| format | Article |
| id | doaj.art-5b8a668741b341338dfe3e02476f4fde |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T11:03:15Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5b8a668741b341338dfe3e02476f4fde2024-01-26T15:35:14ZengMDPI AGCancers2072-66942024-01-0116229410.3390/cancers16020294It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic PerspectiveAnniek Zaalberg0Elisabeth Pottendorfer1Wilbert Zwart2Andries M. Bergman3Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsProstate cancer is the second most common cancer in men worldwide and is associated with high morbidity and mortality. Consequently, there is an urgent unmet need for novel treatment avenues. In addition to somatic genetic alterations, deviations in the epigenetic landscape of cancer cells and their tumor microenvironment (TME) are critical drivers of prostate cancer initiation and progression. Unlike genomic mutations, epigenetic modifications are potentially reversible. Therefore, the inhibition of aberrant epigenetic modifications represents an attractive and exciting novel treatment strategy for castration-resistant prostate cancer patients. Moreover, drugs targeting the epigenome also exhibit synergistic interactions with conventional therapeutics by directly enhancing their anti-tumorigenic properties by “priming” the tumor and tumor microenvironment to increase drug sensitivity. This review summarizes the major epigenetic alterations in prostate cancer and its TME, and their involvement in prostate tumorigenesis, and discusses the impact of epigenome-targeted therapies.https://www.mdpi.com/2072-6694/16/2/294prostate cancerepigeneticstumor microenvironmentandrogen receptor targeted therapyimmunotherapy |
| spellingShingle | Anniek Zaalberg Elisabeth Pottendorfer Wilbert Zwart Andries M. Bergman It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective Cancers prostate cancer epigenetics tumor microenvironment androgen receptor targeted therapy immunotherapy |
| title | It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective |
| title_full | It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective |
| title_fullStr | It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective |
| title_full_unstemmed | It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective |
| title_short | It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective |
| title_sort | it takes two to tango the interplay between prostate cancer and its microenvironment from an epigenetic perspective |
| topic | prostate cancer epigenetics tumor microenvironment androgen receptor targeted therapy immunotherapy |
| url | https://www.mdpi.com/2072-6694/16/2/294 |
| work_keys_str_mv | AT anniekzaalberg ittakestwototangotheinterplaybetweenprostatecanceranditsmicroenvironmentfromanepigeneticperspective AT elisabethpottendorfer ittakestwototangotheinterplaybetweenprostatecanceranditsmicroenvironmentfromanepigeneticperspective AT wilbertzwart ittakestwototangotheinterplaybetweenprostatecanceranditsmicroenvironmentfromanepigeneticperspective AT andriesmbergman ittakestwototangotheinterplaybetweenprostatecanceranditsmicroenvironmentfromanepigeneticperspective |